<DOC>
	<DOC>NCT01256411</DOC>
	<brief_summary>The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.</brief_summary>
	<brief_title>A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients who have successfully completed protocol No. CLCZ696A2219 and who, as judged by the study investigator, are able to continue in the current study. Ability to communicate and comply with all study requirements and demonstrate good medication compliance during CLCZ696A2219. Patients who did not complete CLCZ696A2219. Presence of significant protocol violation in CLCZ696A2219. Patients who are deemed to be unable to comply with the protocol by the investigator. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>LCZ696</keyword>
	<keyword>dual-acting</keyword>
	<keyword>neprilysin</keyword>
	<keyword>nep inhibitor</keyword>
	<keyword>vasopeptidase</keyword>
	<keyword>angiotensin receptor</keyword>
	<keyword>angiotensin receptor neprilysin inhibitor (ARNi)</keyword>
</DOC>